EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Gastrointestinal Transit Time Assessed Using a CT ‐Based Radiopaque Marker Method in Patients With Acute Pancreatitis During Methylnaltrexone Treatment

Cecilie Siggaard Knoph iD, Andreas Svenstrup Hesthaven, Mathias Ellgaard Cook, Srdan Novovic, Mark Berner Hansen, Michael Bau Mortensen, Liv Bjerre Juul Nielsen, Irene Maria Høgsberg, Celina Salomon, Ole Thorlacius-Ussing, Esben Bolvig Mark iD, Jens Brøndum Frøkjær und 2 weitere

Neurogastroenterology & Motility · 2025

DOI: 10.1111/nmo.70027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, 2025. Verfasst von Cecilie Siggaard Knoph und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mech-Sense and Centre for Pancreatic Diseases, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Gastrointestinal Transit, Naltrexone, Narcotic Antagonists, Pancreatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dysmotility is common in acute pancreatitis (AP) and may be evaluated using radiopaque markers and imaging. We present a simple CT‐based approach, which was employed in hospitalized patients with AP.

Methods

This was a secondary analysis of a randomized, controlled trial conducted at four Danish centers. Patients admitted with AP and systemic inflammatory response syndrome were randomized to receive 5 days of intravenous methylnaltrexone or placebo (lactated ringer) added to standard management. Self‐reported stool frequency was documented daily. Patients ingested a capsule containing 10 radiopaque markers on Day 3. A subsequent CT scan on Day 5 was used to identify the location of retained markers for the calculation of gastrointestinal transit, and colonic dimensions (diameters and cross‐sectional areas) were measured.

Results

In total, 47 patients were included. Patients receiving methylnaltrexone less often had laxative treatment (57% vs. 88%, p = 0.01) compared with placebo. Transit times were similar between the methylnaltrexone and the placebo groups (difference, −4 h (95% CI, −16 to 8), p = 0.53). Marker retention scores, colon diameters, and colon cross‐sectional areas did not differ between treatment groups (all p > 0.05). Transit times (ρ = −0.53; p < 0.001), marker retention scores (ρ = −0.42; p = 0.004), diameter (ρ = −0.43; p = 0.003), and cross‐sectional areas (ρ = −0.36; p = 0.01) of the descending colon were negatively correlated with self‐reported stool frequency.

Conclusion

Our CT‐based method was feasible in hospitalized patients with AP. Methylnaltrexone did not change gastrointestinal transit compared with placebo. However, laxative therapy was more frequent with the placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal TransitNaltrexoneNarcotic AntagonistsPancreatitisAdultAgedFemaleHumansMaleMiddle AgedContrast MediaDouble-Blind MethodQuaternary Ammonium CompoundsTomography, X-Ray ComputedSecondary Data Analysis

Stichwörter der Autor:innen

acute pancreatitisgastrointestinal transitmethylnaltrexonemotilityopioid‐antagonists

Substanzen

Contrast MediamethylnaltrexoneNaltrexoneNarcotic AntagonistsQuaternary Ammonium Compounds

Autor:innen und Institutionen

  • Mech-Sense and Centre for Pancreatic Diseases, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Pancreatitis Centre East, Gastro Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Digestive Disease Centre K, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Odense Pancreas Centre, HPB Section, Department of Surgery, Odense University Hospital, Odense, Denmark.

ORCID-Profile: Cecilie Siggaard Knoph, Esben Bolvig Mark

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Knoph, C. S., Hesthaven, A. S., Cook, M. E., Novovic, S., Hansen, M. B., Mortensen, M. B., Nielsen, L. B. J., Høgsberg, I. M., Salomon, C., Thorlacius-Ussing, O., Mark, E. B., Frøkjær, J. B., Olesen, S. S., & Drewes, A. M. (2025). Gastrointestinal Transit Time Assessed Using a CT ‐Based Radiopaque Marker Method in Patients With Acute Pancreatitis During Methylnaltrexone Treatment. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70027

Vancouver

Knoph CS, Hesthaven AS, Cook ME, Novovic S, Hansen MB, Mortensen MB, et al. Gastrointestinal Transit Time Assessed Using a CT ‐Based Radiopaque Marker Method in Patients With Acute Pancreatitis During Methylnaltrexone Treatment. Neurogastroenterology & Motility. 2025. doi:10.1111/nmo.70027

BibTeX
@article{Knoph2025,
  author = {Knoph, Cecilie Siggaard and Hesthaven, Andreas Svenstrup and Cook, Mathias Ellgaard and Novovic, Srdan and Hansen, Mark Berner and Mortensen, Michael Bau and Nielsen, Liv Bjerre Juul and Høgsberg, Irene Maria and Salomon, Celina and Thorlacius-Ussing, Ole and Mark, Esben Bolvig and Frøkjær, Jens Brøndum and Olesen, Søren Schou and Drewes, Asbjørn Mohr},
  title = {Gastrointestinal Transit Time Assessed Using a CT ‐Based Radiopaque Marker Method in Patients With Acute Pancreatitis During Methylnaltrexone Treatment},
  journal = {Neurogastroenterology & Motility},
  year = {2025},
  doi = {10.1111/nmo.70027}
}
Kostenlos starten →